- BD develops, manufactures, and sells medical supplies, laboratory equipment, and diagnostic products among other products.
- With more than 190 countries served, the company operates in the United States, Europe, and Asia. In my opinion, the company’s business activities are well-diversified.
- BDX reported $3 billion, which is not at all a small amount. It means that the company will most likely have sufficient liquidity to finance marketing expenses, and R&D.
- If the management can maintain a portfolio of leading products and solutions as it did in the past, I would expect sales growth to remain positive.
- BDX also promised, in the last annual report, initiatives to reduce complexity across the manufacturing network. These initiatives along with the company’s divestments and merger integration would most likely lead to cost reductions and an increase in the free cash flow margins.
For further details see:
Becton, Dickinson And Company: R&D And M&A Could Make The Price Spike By 47%